Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation

Waldemar E. Wysokinski, Robert D. Mcbane, Paul R. Daniels, Scott C. Litin, David O. Hodge, Nicole F. Dowling, John A. Heit

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

OBJECTIVE: To estimate the 3-month cumulative incidence of thromboembolism (TE), bleeding, and death among consecutive patients with nonvalvular atrial fibrillation (AF) who were receiving long-term anticoagulation therapy and were referred to the Thrombophilia Center at Mayo Clinic for periprocedural anticoagulation management. PATIENTS AND METHODS: In a prospective cohort study of consecutive patients receiving long-term anticoagulation therapy who were referred to the Thrombophilia Center for periprocedural anticoagulation management over the 7-year period, January 1, 1997, to December 31, 2003, 345 patients with nonvalvular AF were eligible for inclusion. Warfarin was stopped 4 to 5 days before and was restarted after surgery as soon as hemostasis was assured. The decision to provide bridging therapy with heparin was individualized and based on the estimated risks of TE and bleeding. RESULTS: The 345 patients with AF (mean ± SD age, 74±9 years; 33% women) underwent 386 procedures. Warfarin administration was not interrupted for 44 procedures. Periprocedural heparin was provided for 204 procedures. Patients receiving heparin were more likely to have prior TE (43% vs 24%; P<.001) and a higher CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score (2.2 vs 1.9; P=.06). Four patients had 6 episodes of TE (3 strokes and 3 acute coronary episodes; TE rate, 1.1%; 95% confidence interval, 0.0%-2.1%). Nine patients had 10 major bleeding events (major bleeding rate, 2.7%; 95% confidence interval, 1.0%-4.4%). There were no deaths. Neither bleeding nor TE rates differed by anticoagulant management strategy. CONCLUSION: The 3-month cumulative incidence of TE and bleeding among patients with AF in whom anticoagulation was temporarily interrupted for an invasive procedure was low and was not significantly influenced by bridging therapy.

Original languageEnglish (US)
Pages (from-to)639-645
Number of pages7
JournalMayo Clinic Proceedings
Volume83
Issue number6
DOIs
StatePublished - 2008

Fingerprint

Thromboembolism
Atrial Fibrillation
Hemorrhage
Heparin
Thrombophilia
Warfarin
Stroke
Confidence Intervals
Incidence
Therapeutics
Hemostasis
Anticoagulants
Cohort Studies
Heart Failure
Prospective Studies
Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wysokinski, W. E., Mcbane, R. D., Daniels, P. R., Litin, S. C., Hodge, D. O., Dowling, N. F., & Heit, J. A. (2008). Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clinic Proceedings, 83(6), 639-645. https://doi.org/10.4065/83.6.639

Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. / Wysokinski, Waldemar E.; Mcbane, Robert D.; Daniels, Paul R.; Litin, Scott C.; Hodge, David O.; Dowling, Nicole F.; Heit, John A.

In: Mayo Clinic Proceedings, Vol. 83, No. 6, 2008, p. 639-645.

Research output: Contribution to journalArticle

Wysokinski, WE, Mcbane, RD, Daniels, PR, Litin, SC, Hodge, DO, Dowling, NF & Heit, JA 2008, 'Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation', Mayo Clinic Proceedings, vol. 83, no. 6, pp. 639-645. https://doi.org/10.4065/83.6.639
Wysokinski WE, Mcbane RD, Daniels PR, Litin SC, Hodge DO, Dowling NF et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clinic Proceedings. 2008;83(6):639-645. https://doi.org/10.4065/83.6.639
Wysokinski, Waldemar E. ; Mcbane, Robert D. ; Daniels, Paul R. ; Litin, Scott C. ; Hodge, David O. ; Dowling, Nicole F. ; Heit, John A. / Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. In: Mayo Clinic Proceedings. 2008 ; Vol. 83, No. 6. pp. 639-645.
@article{444b354335364788af9ce5b8cef569ed,
title = "Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation",
abstract = "OBJECTIVE: To estimate the 3-month cumulative incidence of thromboembolism (TE), bleeding, and death among consecutive patients with nonvalvular atrial fibrillation (AF) who were receiving long-term anticoagulation therapy and were referred to the Thrombophilia Center at Mayo Clinic for periprocedural anticoagulation management. PATIENTS AND METHODS: In a prospective cohort study of consecutive patients receiving long-term anticoagulation therapy who were referred to the Thrombophilia Center for periprocedural anticoagulation management over the 7-year period, January 1, 1997, to December 31, 2003, 345 patients with nonvalvular AF were eligible for inclusion. Warfarin was stopped 4 to 5 days before and was restarted after surgery as soon as hemostasis was assured. The decision to provide bridging therapy with heparin was individualized and based on the estimated risks of TE and bleeding. RESULTS: The 345 patients with AF (mean ± SD age, 74±9 years; 33{\%} women) underwent 386 procedures. Warfarin administration was not interrupted for 44 procedures. Periprocedural heparin was provided for 204 procedures. Patients receiving heparin were more likely to have prior TE (43{\%} vs 24{\%}; P<.001) and a higher CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score (2.2 vs 1.9; P=.06). Four patients had 6 episodes of TE (3 strokes and 3 acute coronary episodes; TE rate, 1.1{\%}; 95{\%} confidence interval, 0.0{\%}-2.1{\%}). Nine patients had 10 major bleeding events (major bleeding rate, 2.7{\%}; 95{\%} confidence interval, 1.0{\%}-4.4{\%}). There were no deaths. Neither bleeding nor TE rates differed by anticoagulant management strategy. CONCLUSION: The 3-month cumulative incidence of TE and bleeding among patients with AF in whom anticoagulation was temporarily interrupted for an invasive procedure was low and was not significantly influenced by bridging therapy.",
author = "Wysokinski, {Waldemar E.} and Mcbane, {Robert D.} and Daniels, {Paul R.} and Litin, {Scott C.} and Hodge, {David O.} and Dowling, {Nicole F.} and Heit, {John A.}",
year = "2008",
doi = "10.4065/83.6.639",
language = "English (US)",
volume = "83",
pages = "639--645",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation

AU - Wysokinski, Waldemar E.

AU - Mcbane, Robert D.

AU - Daniels, Paul R.

AU - Litin, Scott C.

AU - Hodge, David O.

AU - Dowling, Nicole F.

AU - Heit, John A.

PY - 2008

Y1 - 2008

N2 - OBJECTIVE: To estimate the 3-month cumulative incidence of thromboembolism (TE), bleeding, and death among consecutive patients with nonvalvular atrial fibrillation (AF) who were receiving long-term anticoagulation therapy and were referred to the Thrombophilia Center at Mayo Clinic for periprocedural anticoagulation management. PATIENTS AND METHODS: In a prospective cohort study of consecutive patients receiving long-term anticoagulation therapy who were referred to the Thrombophilia Center for periprocedural anticoagulation management over the 7-year period, January 1, 1997, to December 31, 2003, 345 patients with nonvalvular AF were eligible for inclusion. Warfarin was stopped 4 to 5 days before and was restarted after surgery as soon as hemostasis was assured. The decision to provide bridging therapy with heparin was individualized and based on the estimated risks of TE and bleeding. RESULTS: The 345 patients with AF (mean ± SD age, 74±9 years; 33% women) underwent 386 procedures. Warfarin administration was not interrupted for 44 procedures. Periprocedural heparin was provided for 204 procedures. Patients receiving heparin were more likely to have prior TE (43% vs 24%; P<.001) and a higher CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score (2.2 vs 1.9; P=.06). Four patients had 6 episodes of TE (3 strokes and 3 acute coronary episodes; TE rate, 1.1%; 95% confidence interval, 0.0%-2.1%). Nine patients had 10 major bleeding events (major bleeding rate, 2.7%; 95% confidence interval, 1.0%-4.4%). There were no deaths. Neither bleeding nor TE rates differed by anticoagulant management strategy. CONCLUSION: The 3-month cumulative incidence of TE and bleeding among patients with AF in whom anticoagulation was temporarily interrupted for an invasive procedure was low and was not significantly influenced by bridging therapy.

AB - OBJECTIVE: To estimate the 3-month cumulative incidence of thromboembolism (TE), bleeding, and death among consecutive patients with nonvalvular atrial fibrillation (AF) who were receiving long-term anticoagulation therapy and were referred to the Thrombophilia Center at Mayo Clinic for periprocedural anticoagulation management. PATIENTS AND METHODS: In a prospective cohort study of consecutive patients receiving long-term anticoagulation therapy who were referred to the Thrombophilia Center for periprocedural anticoagulation management over the 7-year period, January 1, 1997, to December 31, 2003, 345 patients with nonvalvular AF were eligible for inclusion. Warfarin was stopped 4 to 5 days before and was restarted after surgery as soon as hemostasis was assured. The decision to provide bridging therapy with heparin was individualized and based on the estimated risks of TE and bleeding. RESULTS: The 345 patients with AF (mean ± SD age, 74±9 years; 33% women) underwent 386 procedures. Warfarin administration was not interrupted for 44 procedures. Periprocedural heparin was provided for 204 procedures. Patients receiving heparin were more likely to have prior TE (43% vs 24%; P<.001) and a higher CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score (2.2 vs 1.9; P=.06). Four patients had 6 episodes of TE (3 strokes and 3 acute coronary episodes; TE rate, 1.1%; 95% confidence interval, 0.0%-2.1%). Nine patients had 10 major bleeding events (major bleeding rate, 2.7%; 95% confidence interval, 1.0%-4.4%). There were no deaths. Neither bleeding nor TE rates differed by anticoagulant management strategy. CONCLUSION: The 3-month cumulative incidence of TE and bleeding among patients with AF in whom anticoagulation was temporarily interrupted for an invasive procedure was low and was not significantly influenced by bridging therapy.

UR - http://www.scopus.com/inward/record.url?scp=44949133339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949133339&partnerID=8YFLogxK

U2 - 10.4065/83.6.639

DO - 10.4065/83.6.639

M3 - Article

C2 - 18533080

AN - SCOPUS:44949133339

VL - 83

SP - 639

EP - 645

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -